Skip to main content

[2020-2027] Oncology Drugs Market Size to Reach USD 394.24 Billion by 2027 | Global Market Size, Share, Growth, Trends, Revenue, Sales, Analysis, Report

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Sept. 28, 2020 (GLOBE NEWSWIRE) — The global oncology drugs market size is expected to reach USD 394.24 billion by 2027, exhibiting a CAGR of 11.6% during the forecast period.The growing prevalence of cancer around the world will spur opportunities for this market during the forecast period, states Fortune Business Insights, in a report, titled “Oncology Drugs Market Size, Share & COVID-19 Impact Analysis, By Drugs Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, and Others), By Therapy (Chemotherapy, Targeted Therapy, and Immunotherapy), By Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others), By Dosage Form (Solid, Liquid, and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and Regional Forecast, 2020-2027.” The market size stood at USD 141.33 billion in 2019.Key Development:
April 2019: Sun Pharmaceutical Industries announced the release of INFUGEM injection, which will ve used for the treatment of cancer in the US.The oncology drugs market highlights:An extensive study of regionsForecast value of the marketDetailed analysis of the segmentsCOVID-19 effect on the marketOngoing clinical trials
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/oncology-drugs-market-103431
Surging Pharmaceutical Industry to Contribute Colossal DevelopmentThe ongoing technological advancement in the field of pharmacy is expected to create opportunities for the market during the forecast period. The clinical trials and various drugs in the pipeline can further facilitate the healthy growth of the industry. The growing cases of numerous types of cancer, such as lung cancer, skin cancer, prostate cancer, colon cancer, breast cancer, and others will spur demand for oncology drugs, thus enhancing market growth.According to the World Health Organization (WHO), cancer is a growing burden and the number of new cancer cases is going to rise from 18.1 million in 2018 to 29.4 million by 2040. Moreover, product launches and approvals are expected to have a tremendous impact on the market.The whole world is fighting the novel coronavirus. Sectors and industries are devasted due to the major loss caused by COVID-19 in business. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.
To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/oncology-drugs-market-103431
Positive Impact on Oncology Drugs Market Growth During COVID-19The outbreak of COVID-19 has had a positive impact on the oncology drugs market globally. Certain market segments have witnessed a growth in demand for drugs with respect to the COVID-19 emergency. Panic buying of medications has been witnessed among the cancer patients amid lockdown.The pharmaceutical companies involved in this market have significantly improved their supply chain management, enhanced the capabilities of their R&D, and invested more their manufacturing management and quality control. For instance, according to the quarterly reports of 2020 of Roche, their global supply chain of medicines and tests remain intact and their pharmaceutical division sales increased by 7% as compared to the prior year.
Quick Buy –  Oncology Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/103431
Rising Prevalence to Cancer to Influence Market in North AmericaThe market size in North America is expected to witness a rapid growth rate during the forecast period. The dominance in the region is attributed to the growing prevalence of cancer in the U.S. As per the National Cancer Institute, in 2020, approximately 1.8 million people will be diagnosed with cancer in the U.S.The recent product launches will aid the expansion of the market in the region. Europe is predicted to exhibit a stellar growth rate during the forecast period owing to the growing cancer burden in countries such as U.K., Germany, and France. The market in Asia Pacific is predicted to rise tremendously during the forecast period due to the rising awareness among the population regarding cancer.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/oncology-drugs-market-103431
The Report Lists the Main Companies in the Market:F. Hoffmann-La Roche Ltd (Basel, Switzerland)Genentech, Inc. (California, United States)Novartis AG (Basel, Switzerland)Pfizer Inc. (New York, United States)Bristol-Myers Squibb Company (New York, United States)GlaxoSmithKline plc. (Brentford, United Kingdom)Eli Lilly and Company (Indiana, United States)AstraZeneca (Cambridge, United Kingdom)Sanofi (Paris, France)Bayer AG (Leverkusen, Germany)Other Players
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/oncology-drugs-market-103431
Oncology Drugs Market Segmentations:By Drug Class●             Cytotoxic Drugs•              Alkylating Agents•              Antimetabolites•              Others●             Targeted Drugs•              Monoclonal Antibodies•              Others•              Hormonal Drugs•              OthersBy Therapy•              Chemotherapy•              Targeted Therapy•              ImmunotherapyBy Indication•              Lung Cancer•              Stomach Cancer•              Colorectal Cancer•              Breast Cancer•              Prostate Cancer•              OthersBy Dosage Form•              Solid•              Tablets•              Capsules•              Liquid•              Injectable•              Prefilled Syringes•              OthersBy Distribution Channel•              Hospital Pharmacies•              Retail Pharmacies•              Online Pharmacies•              Others
Have a Look at Related Reports:Lung Cancer Therapeutics Market Share and Global Trend By Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026Breast Cancer Therapeutics Market Share and Global Trend By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Cancer Type (Hormone Receptor, HER2+), and Geography Forecast till 2026Colorectal Cancer Therapeutics Market Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026Vagus Nerve Stimulation (VNS) Market Share & Industry Analysis, By Type (Invasive, and Non-invasive {nVNS}), By Application (Epilepsy, Treatment Resistant Depression (TRD), and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026Spinal Muscular Atrophy (SMA) Treatment Market Share & Industry Analysis, By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Regional Forecast, 2019-2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/global-oncology-drugs-market-10149

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.